

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043466 A1

(51) International Patent Classification⁷: A61K 31/505, 31/196, A61P 35/02

(74) Agents: DOHMANN, George, R. et al.; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(21) International Application Number: PCT/IB2003/005454

(22) International Filing Date: 10 November 2003 (10.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/425,481. 12 November 2002 (12.11.2002) US

(71) Applicant (for all designated States except US): JEWISH GENERAL HOSPITAL [CA/CA]; 3755 Cote St. Catherine Street, Montreal, Quebec H3T 1E2 (CA).

(71) Applicants and

(72) Inventors: PANASCI, Lawrence, Carl [CA/CA]; 1170 Tecumesh, Dollard des Ormeaux, Quebec H9b 2Z4 (CA). ALOYZ, Raquel, Silvia [AR/CA]; 56 Marie Anne est, Montreal, Quebec H2W 1A2 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MW, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.


(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION OF A NITROGEN MUSTARD ANALOGUE AND IMATINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA



(57) Abstract: The invention relates to a combination which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chloraphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrene, prednimustine, trofosfamide or uracil mustard and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamide of formula (I) or a pharmaceutically acceptable salt thereof, the invention pertains to the use of said combination for the treatment chronic lymphocytic leukemia.